FDA Approves First-Ever Plasmid DNA Immunotherapy, Voceryq, for Chronic Airway Growths

In a major medical stride, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voceryq, making it the first plasmid DNA-based immunotherapy ever cleared in the United States. Developed by Inovio Pharmaceuticals, this groundbreaking treatment offers a new hope for adults suffering from recurrent respiratory papillomatosis (RRP), a debilitating condition characterized by chronic, wart-like growths in the airways that often demand repeated surgeries. Voceryq directly tackles the root cause of RRP, targeting the human papillomavirus (HPV) types 6 and 11, which are responsible for these growths. The therapy works by introducing specific DNA plasmids into muscle cells using a special device, effectively training the body's own T cells to recognize and fight the HPV-infected cells. This represents a significant shift from traditional treatments, which primarily involve surgical removal of the growths but don't address the underlying viral infection, leading to frequent recurrences and a relentless cycle of procedures for patients. While Voceryq approval is under an accelerated pathway, based on its ability to significantly reduce the need for surgeries in clinical trials, Inovio Pharmaceuticals anticipates making the treatment available for order within roughly two months, with a full commercial launch slated for early 2027. The FDA has mandated further confirmatory studies to verify its long-term clinical benefits. This landmark approval not only provides a novel, non-surgical option for RRP patients but also paves the way for a new era in DNA-based immunotherapies, potentially impacting other HPV-related diseases and beyond.